TIM-3, a promising target for cancer immunotherapy

He, Yayi, Cao, Jie, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hirsch, Fred·2018·OncoTargets and Therapy
DOI 10.2147/ott.s170385

Cited by (235)

Items 101–200 of 235

  1. Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy
    Xiangyu Meng, Yunfeng Lei, Xuezhong Zhang, Kai Sun, Liming Zhang, Zhifei Wang · 2021 · Applied Materials Today
  2. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization
    Naoshi Odagiri, Hoang Hai, Lê Thị Thanh Thủy, Minh Phuong Dong, Maito Suoh, Kohei Kotani, Atsushi Hagihara, Sawako Uchida‐Kobayashi, Akihiro Tamori, Masaru Enomoto et al. · 2020 · Cancers
  3. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells
    Enrico Munari, Linda Quatrini, Cecilia Ciancaglini, Albino Eccher, Giuseppe Salvatore Bogina, Lorenzo Moretta, Francesca Romana Mariotti · 2022 · Seminars in Immunology
  4. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential
    Reem Saleh, Salman M. Toor, Eyad Elkord · 2020 · Expert Opinion on Therapeutic Targets
  5. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates
    Attila A. Seyhan, Claudio Carini · 2022 · International Journal of Molecular Sciences
  6. Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
    Aswathy R. Devan, Ayana R. Kumar, Bhagyalakshmi Nair, Nikhil Ponnoor Anto, Amitha Muraleedharan, Bijo Mathew, Hoon Kim, Lekshmi R. Nath · 2021 · Pharmaceuticals
  7. The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo
    Tangwu Zhong, Chuanke Zhao, Shuntao Wang, Deshuang Tao, Shuxia Ma, Chengchao Shou · 2020 · Cancer Chemotherapy and Pharmacology
  8. Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T‐cells and regulatory T‐cells in TP53 ‐mutated acute myeloid leukemia
    Milad Abolhalaj, Viktor Sincic, Henrik Lilljebjörn, Carl Sandén, Alar Aab, Karin Hägerbrand, Peter Ellmark, Carl A.K. Borrebaeck, Thoas Fioretos, Kristina Lundberg · 2022 · Cancer Medicine
  9. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy
    Qiaohong Geng, Peifu Jiao · 2024 · Molecules
  10. Checkpoint Inhibitors in Dogs: Are We There Yet?
    Antônio Giuliano, Pedro Antônio Bronhara Pimentel, Rodrigo dos Santos Horta · 2024 · Cancers
  11. Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy
    Pankaj Kumar, Amit Kumar, Sadiya Parveen, John R. Murphy, William R. Bishai · 2019 · Immunotherapy
  12. https://cdrjournal.com/article/view/3531
    Marco Moreira, Cédric Pobel, Nicolas Epaillard, Audrey Simonaggio, Stéphane Marie. Oudard, Yann Alexandre Vano · 2020 · Cancer Drug Resistance
  13. A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
    Hagit Philip, Tom Snir, Miri Gordin, Mikhail Shugay, Alona Zilberberg, Sol Efroni · 2021 · iScience
  14. Tumor microenvironment in salivary gland carcinomas: An orchestrated state of chaos
    Érika Said Abu Egal, João Figueira Scarini, Reydson Alcides de Lima‐Souza, Luccas Lavareze, Patrícia Maria Fernandes, Carolina Emerick, Mayara Trevizol Gonçalves, My N. Helms, ALBINA MESSIAS DE ALMEIDA MILANI ALTEMANI, Fernanda Viviane Mariano · 2022 · Oral Oncology
  15. Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
    Małgorzata Bobrowicz, Radosław Zagożdżon, Joanna Domagała, Roberta Vasconcelos‐Berg, Emmanuella Guenova, Magdalena Winiarska · 2019 · Cancers
  16. Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside
    Amal Kamal Abdel‐Aziz, Mona Kamal Saadeldin, Paolo D’Amico, Stefania Orecchioni, Francesco Bertolini, Giuseppe Curigliano, Saverio Minucci · 2019 · European Journal of Cancer
  17. Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)
    Qiaohong Geng, Juanjuan Xu, Chunsheng Du, Deheng Zhang, Yanrui Jin, Jiatong Song, Wenjing Qu, Changnan Zhang, Gaoxing Su, Peifu Jiao · 2025 · Expert Opinion on Therapeutic Patents
  18. Tim-3 promotes tube formation and decreases tight junction formation in vascular endothelial cells
    Yizi Cong, Xingmiao Wang, Suxia Wang, Guangdong Qiao, Yalun Li, Jianqiao Cao, Wen G. Jiang, Yuxin Cui · 2020 · Bioscience Reports
  19. A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?
    Akshara Vaddi, Holly J. Hulsebus, Emily L. O’Neill, Vijaya Knight, Edward D. Chan · 2024 · Journal of Thoracic Disease
  20. Associations of different immune checkpoints-expressing CD4+ Treg/ T cell subsets with disease-free survival in colorectal cancer patients
    Mohammad A. Al-Mterin, Khaled Murshed, Alhasan Alsalman, Ala Abu-Dayeh, Eyad Elkord · 2022 · BMC Cancer
  21. Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy
    Jhommara Bautista, Carolina E. Echeverría, Ivan Maldonado-Noboa, Joseth Adatty-Molina, Salomé Suárez Urresta, Emily C Coral-Riofrio, Salomé Araujo‐Abad, Nikolaos C. Kyriakidis, Andrés López-Cortés · 2026 · Journal of Immunology Research
  22. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome
    Vinicius Araújo Barbosa de Lima, Annie Borch, Morten Hansen, Arianna Draghi, Iben Spanggaard, Kristoffer Staal Rohrberg, Sine Reker Hadrup, Ulrik Lassen, Inge Marie Svane · 2020 · Cytotherapy
  23. Harnessing NK Cell Checkpoint-Modulating Immunotherapies
    Sachin Kumar Singh Chauhan, Ulrike Koehl, Stephan Kloeß · 2020 · Cancers
  24. The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy
    Ola Hussein, Menatallah Rayan, Tasnim R. Matarid, Dana H. Elkhalifa, Hanan H. Abunada, Lubna Therachiyil, Ashraf A. Khalil, Shahab Uddin M.S., Cristina Maccalli, Hesham Mohamed Korashy · 2025 · Journal of Experimental & Clinical Cancer Research
  25. Current Clinical Investigations in Myelofibrosis
    Sangeetha Venugopal, John O Mascarenhas · 2021 · Hematology/Oncology Clinics of North America
  26. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer
    Bertha Alejandra Martínez-Cannon, Ilaria Colombo · 2024 · Cancer Drug Resistance
  27. Beyond checkpoint inhibitors: the three generations of immunotherapy
    John Schaub,, Shou‐Ching Tang · 2025 · Clinical and Experimental Medicine
  28. Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
    Pratibha Pandey, Fahad Khan, Tarun Kumar Upadhyay, Ramish Maqsood · 2023 · Molecules
  29. Prominent Targets for Cancer Care: Immunotherapy Perspective
    Mehul M. Patel, Aashka Thakkar, Priya R Bhatt, Umang Shah, Ashish D. Patel, Nilay D. Solanki, Swayamprakash Patel, Sandip Patel, Karan Gandhi, Bhaveshkumar A. Patel · 2023 · Current Cancer Therapy Reviews
  30. Reactive oxygen species metabolism-based prediction model and drug for patients with recurrent glioblastoma
    Nian Tan, Jianwei Liu, Ping Li, Zhaoying Sun, Jianming Pan, Wei Zhao · 2019 · Aging
  31. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers
    Tara Jarboe, Neha Y. Tuli, Sanjukta Chakraborty, Rachana R. Maniyar, Nicole DeSouza, Xiu-Min Li, Augustine Moscatello, Jan Geliebter, Raj K. Tiwari · 2021 · Advances in experimental medicine and biology
  32. The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition
    A. Yu. Kuzevanova, Наталья Владимировна Апанович, Danzan Mansorunov, А. А. Коротаева, Alexander Vasil'evich Karpukhin · 2022 · Biomedicines
  33. PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients
    Ming Chen, Jinlian Zhu, Xuedong Yang, Jianxin Yao, Yuqing Liu, Qiang Liu · 2022 · European journal of medical research
  34. Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019)
    Qiaohong Geng, Sagar O. Rohondia, Harras J. Khan, Peifu Jiao, Q. Ping Dou · 2020 · Expert Opinion on Therapeutic Patents
  35. Modulating expression of inhibitory and stimulatory immune ‘checkpoints’ using nanoparticulate-assisted nucleic acid delivery
    Adam Alexander Walters, Baljevan Dhadwar, Khuloud T. Al‐Jamal · 2021 · EBioMedicine
  36. Pancreatic ductal adenocarcinoma microenvironment: Soluble factors and cancer associated fibroblasts as modulators of NK cell functions
    Simona Carlomagno, Chiara Setti, Fulvia Ortolani, Simona Sivori · 2024 · Immunology Letters
  37. Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer
    Xinjie Lu · 2021 · Current Medicinal Chemistry
  38. Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors
    Milena Urbini, Sara Bleve, Giuseppe Schepisi, Cecilia Menna, Giorgia Gurioli, Caterina Gianni, Ugo De Giorgi · 2023 · International Journal of Molecular Sciences
  39. The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors
    Evmorfopoulos, Konstantinos, Marsitopoulos, Konstantinos, Karachalios, Raphael, Karathanasis, Athanasios, Dimitropoulos, Konstantinos, Tzortzis, Vassilios, Zachos, Ioannis, Vlachostergios, Panagiotis J. · 2024 · Cancers
  40. Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
    Sultana Mehbuba Hossain, Chiemi F. Lynch‐Sutherland, Aniruddha Chatterjee, Erin C. Macaulay, Michael Roger Eccles · 2021 · Epigenomes
  41. Highly reliable GIGA-sized synthetic human therapeutic antibody library construction
    Chaoyang Huang, Ying-Yung Lok, Chia-Hui Lin, Szu‐Liang Lai, Yen-Yu Wu, Chih-Yung Hu, Chu‐Bin Liao, Chen‐Hsuan Ho, Yu-Ping Chou, Yi‐Hsuan Hsu et al. · 2023 · Frontiers in Immunology
  42. Immune Checkpoints in Solid Organ Transplantation
    Arnaud Del Bello, Emmanuel Treiner · 2023 · Biology
  43. Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study
    Nicholas J. Skertich, Fei Chu, Imad Tarhoni, Stephen Szajek, Jeffrey Allen Borgia, Mary Beth Madonna · 2022 · Cancers
  44. Lifetime Exposure to Cigarette Smoke and Risk of Ovarian Cancer by T-cell Tumor Immune Infiltration
    Cassandra A. Hathaway, Tianyi Wang, Mary K. Townsend, Christine Vinci, Danielle E. Jake‐Schoffman, Daryoush Saeed‐Vafa, Carlos Moran Segura, Jonathan V. Nguyen, Jose Ramon Conejo-Garcia, Brooke L. Fridley et al. · 2022 · Cancer Epidemiology Biomarkers & Prevention
  45. Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future
    Raphaelly Venzel, Maria Clara Paulino Campos, Larissa Pessoa de Oliveira, Rodrigo Vásquez Dan Lins, Ádamo Davi Diógenes Siena, Kim Tavares Mesquita, Tálita Pollyanna Moreira dos Santos, Nijiro Nohata, Lucas C. M. Arruda, Helioswilton Sales‐Campos et al. · 2023 · Critical Reviews in Oncology/Hematology
  46. Translational Windows in Chordoma: A Target Appraisal
    Samantha E. Hoffman, Sally Al Abdulmohsen, Saksham Gupta, Blake Marie Hauser, David M. Meredith, Ian F. Dunn, Wenya Linda Bi · 2020 · Frontiers in Neurology
  47. Healthy and Patient Type 2 Innate Lymphoid Cells are Differently Affected by in vitro Culture Conditions
    Maryline Falquet, Giuseppe Ercolano, Peter Jandus, Camilla Jandus, Sara Trabanelli · 2021 · Journal of Asthma and Allergy
  48. Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy
    Sepehr Dadfar, Yasamin Eivazzadeh, Haniyeh Molavi, Hoda Abedi, Fatemeh Tavassoli Razavi, Dariush Haghmorad · 2026 · Inflammation Research
  49. The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients
    Fred R. Hirsch, Jill Walker, Brandon W. Higgs, Zachary Aaron Cooper, Rajiv G. Raja, Ignacio Ivan Wistuba · 2021 · Clinical Lung Cancer
  50. T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector
    Ingrid Fert, Laëtitia Douguet, Benjamin Vesin, Fanny Moncoq, Amandine Noirat, Pierre Authié, Sylvain Ciret, Fabien Le Chevalier, Catherine Blanc, Yakov A. Vitrenko et al. · 2024 · npj Vaccines
  51. Acute natural killer cells response to a continuous moderate intensity and a work-matched high intensity interval exercise session in metastatic cancer patients treated with chemotherapy
    Hugo Parent-Roberge, Adeline Fontvieille, Laurence Poirier, Lee‐Hwa Tai, Michel Pavic, Tamàs Fülöp, Éléonor Riesco · 2024 · Brain Behavior & Immunity - Health
  52. Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors
    Somaya A. Abdel‐Rahman, Victor Ovchinnikov, Moustafa Tarek Gabr · 2024 · ACS Medicinal Chemistry Letters
  53. The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers
    Ecem Kalemoglu, Yash C. Jani, Kübra Canaslan, Mehmet Asım Bilen · 2025 · Frontiers in Immunology
  54. Small Molecular Immune Modulators as Anticancer Agents
    Yongxin Han, Li Zhu, Wei Wu, Hui Zhang, Wei Hu, Liguang Dai, Yanqing Yang · 2020 · Advances in experimental medicine and biology
  55. Chimeric Antigen Receptors for the Tumour Microenvironment
    Rosemary Habib, Adnan M. Nagrial, Kenneth P. Micklethwaite, Kavitha Gowrishankar · 2020 · Advances in experimental medicine and biology
  56. Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer
    Chao Liu, Xiaohui Li, Aijie Li, Wenxue Zou, Rui Huang, Xiaoyu Hu, Jinming Yu, Xiaoling Zhang, Jinbo Yue · 2022 · Journal of Immunology Research
  57. Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia
    Saeid Taghiloo, Hossein Asgarian‐Omran · 2023 · Current Treatment Options in Oncology
  58. Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families
    Ran Liu, Xinyan Jiang, Ruijuan Dong, Yuting Zhang, Cong Gai, Wei Jun Peng · 2025 · Frontiers in Immunology
  59. Prediction of the Peptide–TIM3 Binding Site in Inhibiting TIM3–Galectin 9 Binding Pathways
    Ryan E. Odstrcil, Prashanta Dutta, Jin Liu · 2023 · Journal of Chemical Theory and Computation
  60. Characterization of T cell receptor repertoire in penile cancer
    Junying Zhang, Yapeng Wang, Yiqiang Huang, Xintao Tan, Jing Xu, Qian Yan, Jiao Tan, Yao Zhang, Jun Zhang, Qiang Ma et al. · 2024 · Cancer Immunology Immunotherapy
  61. Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
    Haoyue Guo, Yayi He, Peixin Chen, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Caicun Zhou · 2020 · Journal of Thoracic Disease
  62. Overcoming resistant cancerous tumors through combined photodynamic and immunotherapy (photoimmunotherapy)
    Glory Kah, Heidi Abrahamse · 2025 · Frontiers in Immunology
  63. Gatekeepers of immunity: mechanisms and regulation of immune checkpoints and their role in immune-privileged sites
    Reza Nejad Shahrokh Abadi, Z Abadi, Sara Hooshmand · 2025 · Molecular Biology Reports
  64. Therapeutic potential of TIM-3 inhibition in cancer, viral infections, and autoimmune disorders
    Ashira Manzoor, Khaled Barakat · 2025 · The International Journal of Biochemistry & Cell Biology
  65. C-5401331 identified as a novel T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) inhibitor to control acute myeloid leukemia (AML) cell proliferation
    Mesfer Mohammad Al Shahrani, Reem M. Gahtani, Mohammed Makkawi · 2024 · Medical Oncology
  66. Immune checkpoint inhibitors and SARS-CoV2 infection
    Samaneh Abdolmohammadi‐Vahid, Behzad Baradaran, Ian Michael Adcock, Esmaeil Mortaz · 2024 · International Immunopharmacology
  67. Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study
    Nicholas J. Skertich, Fei Chu, Imad Tarhoni, Stephen Szajek, Jeffrey Allen Borgia, Mary Beth Madonna · 2021 · Surgery Open Science
  68. Enhanced cytotoxicity of natural killer cells with Zn-alginate hydrogel microspheres
    Myeongkwan Song, Jiyoung Cheon, Soonjo Kwon · 2024 · Biotechnology and Bioprocess Engineering
  69. Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma
    Titas Banerjee, Anusha Vallurupalli · 2021 · Current Problems in Cancer
  70. ZBED1 Regulates Genes Important for Multiple Biological Processes of the Placenta
    Simone Johansen, Sofie Traynor, Malene Laage Ebstrup, Mikkel G. Terp, Christina Bøg Pedersen, Henrik J. Ditzel, Morten F. Gjerstorff · 2022 · Genes
  71. Tumor Microenvironment Regulates Immune Checkpoints: Emerging Need of Combinatorial Therapies
    Moyna Kalia, Kumari Bhavya, Durba Pal · 2024 · Current Tissue Microenvironment Reports
  72. Comprehensive Characterization of Prognostic Long Noncoding RNAs in Osteosarcoma
    Hua Gao, Yuanyuan Guo, Miaomiao Zhang, Zuqiang Yi · 2020 · BioMed Research International
  73. Emerging IO checkpoints in gastrointestinal oncology
    Alireza Tojjari, Anwaar Saeed, Ludimila L. Cavalcante · 2025 · Frontiers in Immunology
  74. Checkpoint Inhibitors in Bone Metastatic Disease in Solid Tumors
    Victoria A. Wytiaz, Catherine H. Van Poznak · 2023 · Current Osteoporosis Reports
  75. Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm
    Daniel Y. Lee · 2020 · Journal of Immunotherapy and Precision Oncology
  76. Upregulated HAVCR2: A Prognostic and Immune‐Related Marker in Testicular Germ Cell Tumors
    Lei Xue, Xueheng Zhao, Hanbo Jia, Yu Xie, Yuheng Wen, Liang Yu, Zhizhong Liu, Jian Cao, Hao Bo, Lvjun Liu et al. · 2023 · Andrologia
  77. Increased Tim-3 and Gal-9 expression are related to poor prognosis in Oral Squamous Cell Carcinoma
    Sehrish Ahmed, Fouzia Shaikh · 2022 · Research Square
  78. Targeting lung cancer utilizing smart nanoparticles: Nanomedicine meets tumor stroma
    Fang-yu Guo, Yu-zhen Pan · 2025 · Bioorganic Chemistry
  79. The role of bone marrow microenvironment on CAR‐T efficacy in haematologic malignancies
    Dandan Gao, Fei Hong, Aili He · 2023 · Scandinavian Journal of Immunology
  80. Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy
    Jie Zhang, Zhujiang Dai, Cheng Yan, Daorong Wang, Dong Tang · 2021 · Journal of Cancer Research and Clinical Oncology
  81. Oncolytic HSV Vectors and Anti-Tumor Immunity
    Joseph C. Glorioso, Justus B. Cohen, William F. Goins, Bonnie Hall, Joseph W. Jackson, Gary Kohanbash, Nduka A. Amankulor, Balveen Kaur, Michael A. Caligiuri, Ennio Antonio Chiocca et al. · 2020 · Caister Academic Press eBooks
  82. Soluble T Cell Immunoglobulin and Mucin Domain-3 (sTIM-3) Predicts Graft-Versus-Host Disease (GVHD) in Iranian Allogeneic Hematopoietic Stem Cell Transplantation
    Ronak Nalini, Elham Roshandel, Maria Tavakoli Ardakani, Mohammad Hossein Kazemi, Haniyeh Ghaffari Nazari, Abbas Hajifathali, Masoud Soleimani · 2022 · International Journal of Cancer Management
  83. Comprehensive exploration on the role of base excision repair genes in modulating immune infiltration in low-grade glioma
    P Parthipan, Subhadra Kumari, Santosh Kumar, Srinivasan Muthuswamy · 2024 · Pathology - Research and Practice
  84. Generation of highly activated, antigen-specific tumor-infiltrating CD8 + T cells induced by a novel T cell-targeted immunotherapy
    Ava Vila-Leahey, Alecia MacKay, Liliana Portales‐Cervantes, Genevieve M. Weir, Alexandra Merkx-Jacques, Marianne M. Stanford · 2020 · OncoImmunology
  85. Innate and adaptive immunity in cancer
    Aatman S. Doshi, Kirtika H. Asrani · 2021 · Elsevier eBooks
  86. Immune cell exhaustion and apoptotic markers in major depressive disorder: Effects of in vitro cannabidiol administration
    Muanpetch Rachayon, Ketsupar Jirakran, Pimpayao Sodsai, Chavit Tunvirachaisakul, Atapol Sughondhabirom, Jie Li, Yingqian Zhang, Michael H. J. Maes · 2025 · Brain Behavior & Immunity - Health
  87. Targeting T-Cell Immunoglobulin and Mucin Domain 3 with a D -Configured Peptide Radiotracer for Tumor Positron Emission Tomography Imaging
    Jiawen Huang, Jiale Xie, Junyu Bao, Kezhi Ding, Yuting Dai, Xiaochuan Zha, Chuan Chen, Wenhao Liu, Zonghua Luo · 2025 · Bioconjugate Chemistry
  88. It’s a Trap!—Potential of Cathepsins in NET Formation
    Pola Pruchniak, Adrianna Niedzielska, Rafał Nejfeld, Z. Wyżewski, K. Gregorczyk-Zboroch, L. Szulc-Dąbrowska, M. Gieryńska · 2025 · International Journal of Molecular Sciences
  89. PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules
    Liang Mi, Duanhao Gong, Lei Wang, Xue Liang, Jiao Meng, Wei Huang, Jianfeng Zhou · 2021 · Cancer Treatment and Research Communications
  90. TIM3 in COVID-19; A potential hallmark?
    Mohammad Reza Zamani, Pavel Šácha · 2024 · Heliyon
  91. Cancer Immunology and the Evolution of Immunotherapy
    Roza Nurieva, Margarita Divenko, Sang Kim · 2021 · Springer eBooks
  92. HLA AND CANCER
    Александр Сергеевич Голота · 2021 · Physical and rehabilitation medicine medical rehabilitation
  93. Next generation immune checkpoints
    Natalia Muñoz Perez, Kirsten Moziak, Allison M. Martin · 2024 · Elsevier eBooks
  94. PD1/PDL1 and TIM3/Gal9 expression in acute lymphoblastic leukemia: Gal-9 expression on leukemia stem cells as an independent prognostic parameter
    Azza M. Kamel, Abdallah M Almuslimani, Emad H. Kandil, Marwa Hanafy, Mohamed Samra, Youssef Madney, Randa Amin Osman · 2025 · BMC Cancer
  95. El microambiente peritumoral en la patogénesis del cáncer de próstata
    Elizabeth Vargas, Dayana Rodríguez Morales, Rafael Santiago Parra-Medina · 2025 · Revista Colombiana de Cancerología
  96. New potential checkpoint inhibitors in cancer therapy
    Jindřich Kopecký · 2022 · Onkologie
  97. A New Method for Constructing Macrophage-Associated Predictors of Treatment Efficacy Based on Single-Cell Sequencing Analysis
    Jianxiu Lin, Yang Ran, Tengfei Wu, Zishan Wang, Jinjin Zhao, Yun Tian · 2023 · Journal of Immunotherapy
  98. The Functional Cancer Immunity Cycle
    Ann Hanna, Justin Micah Balko · 2024 · Cancer immunotherapy
  99. Diagnostic and prognostic value of CD44v9 and TIM3 expression in CK‑ and CK+ regions in gastric cancer tissues
    Xiaofei Wang, Lin Lü, Ruidong Yang, Zhiwu Wang, Qingke Li, Jingwu Li, Yankun Liu · 2024 · Oncology Letters
  100. Body Composition in Cholangiocarcinoma Affects Immune Cell Populations in the Tumor and Normal Liver Parenchyma
    Guanwu Wang, Dong Liu, Tarick M. Al‐Masri, Carlos Constantin Otto, Jens Thomas Siveke, Sven Arke Lang, Tom Florian Ulmer, Steven W.M. Olde Damink, Tom Luedde, Edgar Dahl et al. · 2024 · Journal of Clinical and Experimental Hepatology